Company News
Lupin Receives Tentative US FDA Approval for Dimethyl Fumarate Delayed Release Capsules
Lupin’s Dimethyl Fumarate Delayed Release Capsules, 120 mg and 240 mg is the generic version of Biogen, Inc’s Tecfidera Capsules, 120 mg and 240 mg. It is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Lupin’s Apixaban Tablets, 2.5 mg and 5 mg is the generic version of Bristol-Myers Squibb Company’s Eliquis Tablets, 2.5 mg and 5 mg. It is indicated for Tecfidera Capsules, 120 mg and 240 mg had annual sales of approximately USD 3545.4 million in the US (IQVIA MAT September 2018). – Medical Buyer Bureau